AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02567981 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cereal Fortificado (Fortified Cereal)
Description: Cereal Fortificado Dose: 45g/day. Contains the following daily amounts per dose: Vitamin A 226.6mcg, Thiamine 0.058mg, Riboflavin 0.202mg, Niacin 2.16mg, Panthotenic acid 3.015mg, Vitamin B6 0.765mg, Folate 27mcg, Vitamin B12 0.9mg, Vitamin C 45mg, Vitamin D 1.8mcg, Vitamin E 3.735mg, Vitamin K 45mcg, iron 3.6mg, Zinc 1.8mg, Iodine 18mcg, potassium 180mg, phosphorus 90 mg, calcium 58.50mg. Percentage weight: 58% corn, 20% soy, Skim dry milk 8%, Sugar 9%, Soy Oil 3%, Vitamins and Minerals 0.2%, calcium phosphate 1.23%, Potassium chloride 0.27%. Energy 184.5 kcal, protein 7.2%, Fat 4.1%, Fiber 1.4%, Ash 4.6%.
Study NCT02567981 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous sulphate
Description: Ferrous sulfate drops children \<12 months: 12,5mg elemental iron/day (continuous). Children from 12-23.9months: elemental iron 25mg/day (continuous).~Chidlren from 24 to 59 months: 1ml/day for two months, every 6 months.
Study NCT03071367 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Simulation
Study NCT03408561 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-Based Intervention
Description: Receive message via Twitter
Study NCT03408561 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study NCT02274974 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: •The wound of C.Swill be infiltrated before closure of the skin, with 20 ml of 2% lidocaine.
Study NCT02567981 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin A
Description: Vitamin A Capsules: children \<12 months: 100.000 IU/6 months. Children 12-59 months: 200.000 IU/6 months.
Study NCT03991845 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vit D
Description: Vit D supplementation was done
Study NCT02274974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine and Epinephrine
Description: The wound of C.S will be infiltrated before closure of the skin, with 20 ml of 2% lidocaine and epinephrine in related dose manner 1:200.000.
Study NCT02730598 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hybrid Training System (HTS)
Description: Electrodes (15 cm x 6 cm) will be placed over the quadriceps and electrodes (11 cm x 6 cm) (Sekisui Plastics Co., Tokyo, Japan) will be placed over the hamstrings. Electrical stimulation parameters will be based on a standard Russian waveform in which a 5,000 Hz carrier frequency is modulated at 40 Hz (2.4 ms on, 22.6 ms off) to deliver a rectangular voltage biphasic pulse. Acceleration sensors as a joint motion sensor (EWTS9PD, Home Appliances Development Center Corporate Engineering Division, Appliances Company Panasonic Corporation 2-3-1-2 Noji-higashi,Kusatsu City, Shiga, Japan) is placed on the front of each leg 88mm above the patellar edge. It analyzes the algorithm of each exercise pattern, and stimulates the antagonist of the motion of each bilateral knee joint during exercise. Electrical stimulation intensity will be set to \~50-60% of 1RM based on the subject's tolerance. The subject's tolerance gradually increases, and electrical stimulation intensity is reset every 2 weeks.
Study NCT02730598 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sensory TENS
Description: The electrical stimulation intensity will be set under the muscle contraction threshold (but at a level at which the subject can perceive as sensory TENS). Electrical stimulation parameters (i.e. waveform and pulse duration) will be the same of HTS, while the amplitude will be lower. The subject will be stimulated using the same device as for HTS.
Study NCT03991845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vit D
Description: Vit D supplementation was done
Study NCT04632888 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telephone support for breastfeeding follow-up
Description: The researcher, after the mother is discharged, by making a video call by phone every day for the first week, providing counseling to the mother on matters that she needs and recording it in the Baby Monitoring Form The researcher gives the mother a video
Study NCT02677935 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community education programs
Study NCT00874146 — intervention group
Intervention type: GENETIC
Intervention: Fluorescent in-situ hybridization (FISH)
Description: Dual color FISH test to assess ratio of HER2/neu amplification
Study NCT02659800 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT04018053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-fluciclovine
Description: 18F-fluciclovine is a new radiotracer. This radiotracer targets amino-acid transporters, which are overexpressed in multiple cancers.
Study NCT04018053 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/CT
Description: Positron emission tomography/computed tomography (PET/CT) uses small amounts of radioactive materials called radiotracers, a special camera and a computer to help evaluate organ and tissue functions.
Study NCT02659800 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NT-I7
Description: Given IM
Study NCT01843036 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Durham Connects
Description: Durham Connects begins with a visit during the birthing hospital stay, followed by 1-3 nurse home visits between 4-12 weeks of infant age, and then a follow-up contact one month later. During the visits, the nurse engages with the mother and completes a health and psychosocial assessment, during which she systematically assesses risk and family needs in 12 important empirically-derived areas of family functioning across 4 domains (i.e. - healthcare, parenting/childcare, family violence/safety, and maternal well-being). For each domain found to be at risk, the nurse intervenes directly to support the mother (mild risk) or connects the mother with matched community resources as needed to address individualized long-term family needs (moderate or severe risk).
Study NCT02922725 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-hydroxytryptophan and Creatine
Study NCT02922725 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control
Study NCT04434417 — intervention group
Intervention type: DEVICE
Intervention: 2019-nCoV IgG/IgM Rapid Test Cassette
Description: The specimen (whole blood, serum, plasma) will be loaded into the cassette and will migrate via capillary action along the membrane to react with the gold conjugate. The result will be available in 10 minutes
Study NCT03925623 — intervention group
Intervention type: OTHER
Intervention: Novel approaches for the design of child resistant closures
Description: Two novel designs for child resistant closures are tested.~One is sized based on the anthropometric properties of adults and children's hands such that it should disallow children from engaging the system and enable adults (the physically based design strategy). The other replicates the first design, but is sized such that either of the two populations should be able to engage the closure.~In testing this way, we begin to differentiate the paradigm that holds the children out (the cognitively based design strategy-- they do not understand and/or a physical one- they are unable to use the closure).~Results (proportion of children opening within the first or second five minute periods of test and time to opening during the same) from each of these, will be compared to results from the third treatment, a standard, commercially available push and turn system.
Study NCT02659800 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Given IM
Study NCT01224392 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chemoradiotherapy
Description: Radiotherapy (23 x 2 Gy) + capecitabine 825mg/m2 p.o. twice daily, excluding weekends
Study NCT01224392 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy with boost
Description: Radiotherapy (23 x 2 Gy), with a simultaneous integrated boost up to 55.2 Gy on the primary tumor
Study NCT02434068 — intervention group
Intervention type: OTHER
Intervention: CT
Description: followup
Study NCT00642733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib [Tarceva]
Description: 100mg po daily
Study NCT00642733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: 1000mg/m2 iv weekly for 8 weeks, then weekly for 3 weeks of each 4 week cycle
Study NCT00218660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: 150mg/day Naltrexone
Study NCT00218660 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BRENDA
Description: Psychosocial Treatment
Study NCT00218660 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: BRENDA
Description: Psychosocial Treatment
Study NCT00218660 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT
Description: Cognitive Behavioral Therapy
Study NCT00218660 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: CBT
Description: Cognitive Behavioral Therapy
Study NCT00218660 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01121796 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Study NCT01121796 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Water or milk
Study NCT01121796 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D enriched milk
Study NCT01736111 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: one way text
Study NCT01736111 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personal feedback
Study NCT03007550 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic total gastrectomy
Description: LTG with D1+/D2-10 lymphadenectomy for patients with clinical stage I (T1N0M0、T1N1M0、T2N0M0) gastric adenocarcinoma
Study NCT03007550 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Open total gastrectomy
Description: OTG with D1+/D2-10 lymphadenectomy for patients with clinical stage I (T1N0M0、T1N1M0、T2N0M0) gastric adenocarcinoma
Study NCT01071044 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lisdexamfetamine Dimesylate
Description: Will be randomly assigned to one of two treatment arms in a 1:1 ratio of either LDX or placebo for 6 weeks. Subjects will be started with a single pill containing 30mg of LDX or comparable placebo, depending on the treatment assignment. At the week 2 visit, the dose will be increased to 50 mg (or comparable placebo) if the patient exhibits no significant adverse effects as judged by the Investigator. At the week 4 visit, the dose will be increased to 70 mg (or comparable placebo) if the patient exhibits no significant adverse effects as judged by the investigator.
Study NCT01071044 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 30, 50 or 70 mg
Description: Will be randomly assigned to one of two treatment arms in a 1:1 ratio of either LDX or placebo for 6 weeks. Subjects will be started with a single pill containing 30mg of LDX or comparable placebo, depending on the treatment assignment. At the week 2 visit, the dose will be increased to 50 mg (or comparable placebo) if the patient exhibits no significant adverse effects as judged by the Investigator. At the week 4 visit, the dose will be increased to 70 mg (or comparable placebo) if the patient exhibits no significant adverse effects as judged by the investigator.
Study NCT04244838 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Gait Analysis
Description: The patients will undergo Gait analysis (integrated movement analysis system) performed at the Complex Laboratory for Movement Analysis and functional-clinical evaluation of the prosthesis of the Rizzoli Orthopedic Institute. The instrumentation used in the Movement Analysis Laboratory consists of a stereophotogrammetric system equipped with eight infrared cameras (Vicon® 460-Oxford system) and 2 dynamometric platforms (Kistler® Instrument, AG Switzerland). The IOR GAIT protocol will be used as a marker set (Leardini et al. 2007). For the evaluation of muscle activation, surface electromyography with 16-channel system will be used (ZeroWire Cometa, Milan). Spatio-temporal parameters, kinematics, kinetics and muscle activation will be evaluated.
Study NCT00822523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin, Type A
Description: 20 units, single dose, intramuscular in right EDB muscle
Study NCT00822523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin, Type A
Description: 2 units, single dose, intramuscular to right EDB muscle
Study NCT00822523 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Single Dose, Intramuscular into right EDB muscle
Study NCT02641574 — intervention group
Intervention type: OTHER
Intervention: compare complication
Study NCT01324596 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous
Description: Chemoimmunotheraphy
Study NCT01324596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Chemoimmunotheraphy
Study NCT04491266 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: FBA
Description: N-(1-carbamoyl-2-phenyl-ethyl) butyramide (FBA) has been developed.
Study NCT04491266 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: maltodextrins
Study NCT00760773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacidophil (experimental high dose)
Description: Each sachet will contain a minimum of 4 billion CFU/sachet. The total weight of all ingredients is 1 gm. All patients in this arm of the study will take 1 sachet twice daily for 5 days. Doses should be ideally separated by 12 hours (minimum of 8 hours) and taken within 30 minutes of food/drink. If the child vomits within 15 minutes of medication administration (initial or subsequent dose), the dose will be repeated. Subjects in this arm will receive the high dose which will consist of 4 billion CFU (1 active sachet) PO BID (total daily dose = 8 billion CFU) x 5 days.
Study NCT00760773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacidophil (experimental standard dose)
Description: Each sachet will contain a minimum of 4 billion CFU/sachet. The total weight of all ingredients is 1 gm. All patients in this arm of the study will take 1 sachet twice daily for 5 days. Doses should be ideally separated by 12 hours (minimum of 8 hours) and taken within 30 minutes of food/drink. If the child vomits within 15 minutes of medication administration (initial or subsequent dose), the dose will be repeated. Subjects in this arm will receive the standard dose which will consist of 4 billion CFU (1 active sachet) PO QAM (total daily dose = 4 billion CFU) plus 1 placebo sachet PO QHS x 5 days.
Study NCT00760773 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The total weight of all ingredients is 1 gm. All patients in this arm of the study will take 1 sachet twice daily for 5 days. Doses should be ideally separated by 12 hours (minimum of 8 hours) and taken within 30 minutes of food/drink. If the child vomits within 15 minutes of medication administration (initial or subsequent dose), the dose will be repeated.
Study NCT05367115 — intervention group
Intervention type: OTHER
Intervention: longitudinal observational study
Description: longitudinal observational study
Study NCT01522469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crenolanib Besylate (CP-868,596-26)
Description: Subjects will take crenolanib 200mg/m2/day divided in three doses daily (preferably every eight hours), taken orally at least 30 minutes pre or post meal until disease progression, death, or the patient discontinues treatment for adverse events, investigator's judgment, or other reasons. Patients who are able to proceed to allogeneic stem cell transplant will be able to resume crenolanib therapy post-transplant in an attempt to maintain remission.
Study NCT04241601 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interleukin-2 [IL-2]
Description: Active Comparator: IL-2 plays a key role in Treg cell development, expansion, survival and suppressive function
Study NCT04241601 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Dextrose 5% solution
Description: Placebo Comparator: Dextrose 5% solution
Study NCT03083925 — intervention group
Intervention type: DEVICE
Intervention: TIPS
Description: Transjugular Intrahepatic Portosystemic Shunt
Study NCT02439047 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biological samples collection
Description: -Peritoneal samples : will be collected during abdominal surgery~A biopsy from 1 to 2 cm2 will be performed in healthy peritoneum~- Adipose tissue samples : will be collected during surgery for breast reconstruction
Study NCT00563888 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NET
Description: Narrative Exposure Therapy for traumatized survivors of organized violence
Study NCT01034514 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real-time Position Management system
Description: Standard of Care
Study NCT01034514 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Discovery ST multislice PET/CT scanner
Description: Standard of Care
Study NCT01034514 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Infinia Hawkeye SPECT/CT gamma camera
Description: Standard of Care
Study NCT01034514 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pinnacle3 treatment planning system
Description: Standard of Care
Study NCT01034514 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SKYLight nuclear camera
Description: Standard of Care
Study NCT01034514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTPA
Description: 1 mCi; inhalation
Study NCT01034514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TECHNETIUM TC 99M MAA
Description: 3 mCi; iv
Study NCT03694275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Soticlestat
Description: TAK-935 tablets
Study NCT01274845 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Heliox mechanical ventilation
Description: Mechanical ventilation (MV) with air-oxygen at baseline, then 1 hour of heliox (helium-oxygen) MV and then return to MV with air-oxygen.
Study NCT00743301 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Palm olein vs olive oil and lard
Description: 17E% from test fat is incorporated into three rolls and a piece of cake
Study NCT00743301 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Palm olein vs olive oil and lard
Description: 17E% from test fat is incorporated into three rolls and a piece of cake
Study NCT03394001 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Wound infiltration
Description: Before skin closure,the subcutaneous tissue and skin all around the wound will be infiltrated by 20 mL of the drug then closure of the skin will be done.
Study NCT03394001 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine Hydrochloride
Description: 20 ml of 1% Lidocaine solution
Study NCT03394001 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac tromethamine
Description: 20 mL of saline with 30 mg ketorolac
Study NCT03849313 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: AVT02, a proposed similar biological product (biosimilar) of Humira which contains adalimumab . Adalimumab is a recombinant, fully human monoclonal immunoglobulin G1 (IgG1) antibody that binds specifically and with high affinity to the soluble and transmembrane forms of tumor necrosis factor (TNF)-α thereby inhibiting the binding of TNF-α with its receptor, and inhibiting TNF -α's biological function.~Tumor necrosis factor-α is a naturally occurring cytokine that is key to normal inflammatory and immune responses. Elevated levels of TNF-α are found in the synovial fluid of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis patients and psoriasis plaques and play an important role in both the pathologic inflammation and joint destruction that are hallmarks of these inflammatory diseases
Study NCT03856970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Microgestin®
Description: 30 μg/1500 μg tablets for oral administration
Study NCT03856970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levothyroxine
Description: 600 μg tablets for oral administration
Study NCT03856970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glyburide
Description: 5 mg tablets for oral administration
Study NCT03856970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: 0.25 mg tablets for oral administration
Study NCT03856970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IW-3718
Description: 500-mg film-coated tablets for oral administration
Study NCT04132479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin 500mg
Description: 1000mg taken orally every 12 hours for 5 days
Study NCT04132479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin 500mg
Description: 1000mg taken orally every 12 hours for 5 days
Study NCT04132479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tinidazole 500mg
Description: 500mg taken orally every 12 hours for 5 days
Study NCT04132479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole 20mg
Description: 20mg taken orally every 12 hours for 5 days
Study NCT04132479 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin 500mg
Description: 1000mg taken orally every 12 hours for 14 days